|
A.V. Fateeva, E.V. Eliseeva, V.I. Apanasevich, A.A. Zaemskaya
Analysis of pharmacotherapy in patients with HR+HER2- metastatic breast cancer with PIK3CA mutations in real clinical practice
|
№7 / 2024
|
|
De V.A., Kochetkov A.I., Abdullaev Sh.P., Bochkov P.O., Klepikova M.V., Batyukina S.V., Mirzaev K.B., Ostroumova O.D.
On the possible relationship between polymorphic variants of the CYP2C19 gene, residual concentration and the presence of bleeding in patients who have suffered acute coronary syndrome and are receiving clopidogrel as part of dual antithrombotic therapy
|
№6 / 2024
|
|
Shatalova N.A., Mirzaev K.B., Abdullaev Sh.P., Sozaeva Zh.A., Bochkov P.O., Asoskova A.V., Denisenko N.P., Kochetkov A.I., Ebzeeva E.Yu., Chernyaeva M.S., Shastina V.R., Ostroumova O.D., Sychev D.A.
On the possible relationship between the presence of polymorphic variants of CYP3A4/5 cytochrome genes, their metabolic activity with rivaroxaban pharmacokinetics and the development of bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease
|
№1 / 2024
|
|
E.O. Golubenko, M.I. Savelyeva, I.V. Poddubnaya, V.V. Korennaya
Possibilities of a pharmacogenetic approach to solving gynecological problems in patients taking tamoxifen: a literature review
|
№11 / 2023
|
|
D.V. Ivashchenko, A.Yu. Kravchenko, S.Z. Khoang, N.I. Buromskaya, P.V. Shimanov, R.V. Deitch, M.I. Nastovich, K.A. Akmalova, A.A Kachanova, L.M. Savchenko, Yu.S. Shevchenko, D.A. Sychev
Pharmacogenetic factors of haloperidol’s safety in adolescents experiencing acute psychotic episodes
|
№4-5 / 2023
|
|
E.O. Golubenko, M.I. Savelyeva, Zh.A. Sozaeva, I.V. Poddubnaya, V.V. Korennaya
Clinical significance of genetic polymorphism of tamoxifen metabolic enzymes and transporters in breast cancer: results of a population-based cohort study
|
№11-12 / 2022
|
|
O.D. Guryeva, M.I. Savelyeva, T.T. Valiev
Influence of pharmacogenetic parameters on clinical variants of methotrexate toxicity in acute lymphoblastic leukemia in children
|
№7 / 2022
|
|
D.V. Ivashchenko (1, 2), N.I. Buromskaya (3), P.V. Shimanov (3), R.V. Deich (3), I.V. Dorina (3), M.I. Nastovich (3), K.A. Akmalova (1), A.A. Kachanova (1), E.A. Grishina (1), L.M. Savchenko (1), Yu.S. Shevchenko (1), D.A. Sychev (1)
Pharmacogenetic predictors of the efficacy and safety of antipsychotics in adolescents with an acute psychotic episode
|
№11 / 2021
|
|
P.B. Shorokhova, V.L. Baranov, N.V. Vorokhobina, O.S. Shpilevaya
Genetic predictors of the pharmacological effects of dipeptidyl peptidase-4 inhibitors and sulfonylureas in patients with type 2 diabetes mellitus
|
№4 / 2019
|
|
E.V. Ivanova (1), E.A. Mezhevitinova (2), A.E. Donnikov (2), I.G. Nikitin (3), V.N. Prilepskaya (2)
PHARMACOGENETIC ASPECTS OF COMBINED HORMONAL CONTRACEPTION
|
№3 / 2016
|
|
A.A. Moiseyev
ROLE OF PHARMACOGENETICS IN INDIVIDUALIZING OF ANTICANCER CHEMOTHERAPY
|
№8 / 2013
|
Русский
